Desloratadine use while Breastfeeding
Drugs containing Desloratadine: Clarinex, Aerius, Clarinex-D 12 Hour, Clarinex-D 24 Hour, Clarinex Reditabs, Neoclarityn
Desloratadine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Because of its expected low milk levels and lack of sedation and anticholinergic effects, maternal use of desloratadine is unlikely to affect a breastfed infant or milk production. Desloratadine might have a negative effect on lactation in combination with a sympathomimetic agent such as pseudoephedrine.
Desloratadine is the active metabolite of loratadine and is marketed separately as a drug product.
Maternal Levels. Milk levels have not been measured after desloratadine administration. However, after a single oral dose of 40 mg of its parent compound loratadine in 6 women, average desloratadine peak milk levels of 16 mcg/L (range 9 to 29.6) were measured. The total amount excreted in milk over 48 hours was 6 mcg (range 3.7 to 11.6). However, the loratadine dose was 10 times the recommended dose of desloratadine of 5 mg, assuming 100% conversion of loratadine to desloratadine and adjusting for the differences in molecular weight. The calculated maximum expected doses of desloratadine in milk was 0.42% of the maternal weight-adjusted dose of loratadine after the 40 mg loratadine dose.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Antihistamines in relatively high doses given by injection can decrease basal serum prolactin in nonlactating women and in early postpartum women. However, suckling-induced prolactin secretion is not affected by antihistamine pretreatment of postpartum mothers. Whether lower oral doses of antihistamines have the same effect on serum prolactin or whether the effects on prolactin have any consequences on breastfeeding success have not been studied. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Alternate Drugs to Consider
1. Hilbert J, Radwanski E, Affine MB et al. Excretion of loratadine in human breast milk. J Clin Pharmacol. 1988;28:234-9. PMID: 2966185
2. Messinis IE, Souvatzoglou A, Fais N. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 1985;8:143-6. PMID: 3928731
3. Pontiroli AE, De Castro e Silva E, Mazzoleni F et al. The effect of histamine and H1 and H2 receptors on prolactin and luteinizing hormone release in humans: sex differences and the role of stress. J Clin Endocrinol Metab. 1981;52:924-8. PMID: 7228996
CAS Registry Number
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
More about desloratadine
- Desloratadine orally disintegrating tablets
- Desloratadine syrup
- Desloratadine (Advanced Reading)